David Mathes
Concepts (382)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 37 | 2025 | 105 | 10.140 |
Why?
| | Perforator Flap | 13 | 2024 | 31 | 5.270 |
Why?
| | Vascularized Composite Allotransplantation | 5 | 2024 | 31 | 3.240 |
Why?
| | Surgical Flaps | 12 | 2024 | 130 | 3.180 |
Why?
| | Surgery, Plastic | 9 | 2025 | 45 | 2.960 |
Why?
| | Transplantation Tolerance | 9 | 2024 | 36 | 2.680 |
Why?
| | Graft Survival | 16 | 2024 | 534 | 2.390 |
Why?
| | Graft Rejection | 14 | 2024 | 620 | 2.220 |
Why?
| | Epigastric Arteries | 14 | 2024 | 26 | 2.140 |
Why?
| | Rectus Abdominis | 5 | 2024 | 17 | 1.910 |
Why?
| | Skin Transplantation | 9 | 2018 | 85 | 1.750 |
Why?
| | Free Tissue Flaps | 5 | 2024 | 52 | 1.700 |
Why?
| | Microsurgery | 10 | 2024 | 75 | 1.660 |
Why?
| | Myocutaneous Flap | 3 | 2024 | 10 | 1.560 |
Why?
| | Composite Tissue Allografts | 4 | 2016 | 8 | 1.540 |
Why?
| | Facial Transplantation | 5 | 2014 | 10 | 1.530 |
Why?
| | Breast Implants | 5 | 2024 | 19 | 1.430 |
Why?
| | Postoperative Complications | 19 | 2025 | 2639 | 1.400 |
Why?
| | Hand Transplantation | 5 | 2011 | 9 | 1.370 |
Why?
| | Breast Neoplasms | 16 | 2025 | 2234 | 1.370 |
Why?
| | Surgical Wound Dehiscence | 4 | 2024 | 22 | 1.180 |
Why?
| | Breast Implantation | 4 | 2024 | 13 | 1.150 |
Why?
| | Immune Tolerance | 8 | 2024 | 362 | 1.150 |
Why?
| | Transplantation Chimera | 6 | 2014 | 54 | 1.110 |
Why?
| | Bone Marrow Transplantation | 6 | 2014 | 286 | 1.080 |
Why?
| | Acellular Dermis | 3 | 2022 | 11 | 1.030 |
Why?
| | Transplantation, Homologous | 14 | 2016 | 415 | 1.010 |
Why?
| | Fat Necrosis | 2 | 2022 | 9 | 0.930 |
Why?
| | Angiography | 5 | 2022 | 207 | 0.900 |
Why?
| | Iliac Artery | 1 | 2024 | 55 | 0.870 |
Why?
| | Breast | 5 | 2024 | 149 | 0.850 |
Why?
| | Immunosuppressive Agents | 8 | 2024 | 889 | 0.850 |
Why?
| | Body Dysmorphic Disorders | 1 | 2023 | 12 | 0.840 |
Why?
| | Rhinoplasty | 1 | 2023 | 29 | 0.820 |
Why?
| | Preoperative Care | 5 | 2012 | 356 | 0.810 |
Why?
| | Immunotoxins | 4 | 2025 | 55 | 0.800 |
Why?
| | Enoxaparin | 1 | 2023 | 63 | 0.790 |
Why?
| | Retrospective Studies | 35 | 2025 | 15504 | 0.780 |
Why?
| | Vascular Surgical Procedures | 2 | 2019 | 299 | 0.770 |
Why?
| | Venous Thromboembolism | 2 | 2023 | 313 | 0.770 |
Why?
| | Surgical Wound Infection | 7 | 2024 | 305 | 0.760 |
Why?
| | Transplant Donor Site | 1 | 2021 | 3 | 0.740 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 24 | 0.730 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2016 | 614 | 0.710 |
Why?
| | Pressure Ulcer | 2 | 2011 | 46 | 0.680 |
Why?
| | Humans | 88 | 2025 | 136764 | 0.660 |
Why?
| | Craniosynostoses | 3 | 2025 | 57 | 0.660 |
Why?
| | Abdominal Wall | 2 | 2010 | 24 | 0.640 |
Why?
| | Anticoagulants | 2 | 2023 | 663 | 0.620 |
Why?
| | Diphtheria Toxin | 4 | 2025 | 66 | 0.610 |
Why?
| | Mastectomy | 7 | 2024 | 136 | 0.600 |
Why?
| | Tissue Transplantation | 3 | 2012 | 10 | 0.590 |
Why?
| | Kidney Transplantation | 5 | 2012 | 701 | 0.580 |
Why?
| | Nipples | 1 | 2018 | 9 | 0.580 |
Why?
| | Swine | 11 | 2024 | 773 | 0.570 |
Why?
| | Models, Animal | 4 | 2024 | 384 | 0.550 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2016 | 22 | 0.530 |
Why?
| | Female | 53 | 2025 | 72787 | 0.520 |
Why?
| | Tomography, X-Ray Computed | 3 | 2012 | 2667 | 0.510 |
Why?
| | Tissue and Organ Harvesting | 2 | 2014 | 70 | 0.500 |
Why?
| | Patient Safety | 1 | 2019 | 308 | 0.490 |
Why?
| | Bone Marrow Cells | 1 | 2016 | 316 | 0.480 |
Why?
| | Frontal Bone | 2 | 2025 | 21 | 0.460 |
Why?
| | Groin | 1 | 2014 | 9 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1301 | 0.450 |
Why?
| | Perineum | 1 | 2014 | 32 | 0.450 |
Why?
| | Orbit | 2 | 2025 | 70 | 0.440 |
Why?
| | Pregnancy, Animal | 1 | 2014 | 52 | 0.440 |
Why?
| | Patient Satisfaction | 3 | 2024 | 656 | 0.440 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2014 | 32 | 0.440 |
Why?
| | Bone Transplantation | 3 | 2025 | 90 | 0.430 |
Why?
| | Negative-Pressure Wound Therapy | 2 | 2024 | 27 | 0.430 |
Why?
| | Middle Aged | 26 | 2025 | 33228 | 0.430 |
Why?
| | Treatment Outcome | 17 | 2024 | 10744 | 0.430 |
Why?
| | Swine, Miniature | 8 | 2024 | 82 | 0.420 |
Why?
| | Pelvis | 1 | 2014 | 102 | 0.420 |
Why?
| | Interleukin-2 | 4 | 2024 | 455 | 0.420 |
Why?
| | Dogs | 5 | 2016 | 411 | 0.400 |
Why?
| | Facial Injuries | 2 | 2009 | 21 | 0.390 |
Why?
| | Face | 2 | 2013 | 173 | 0.380 |
Why?
| | Prosthesis-Related Infections | 2 | 2024 | 95 | 0.360 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2023 | 43 | 0.360 |
Why?
| | Communications Media | 1 | 2011 | 4 | 0.360 |
Why?
| | Adult | 25 | 2025 | 37630 | 0.360 |
Why?
| | Abdomen | 3 | 2024 | 125 | 0.360 |
Why?
| | Attitude of Health Personnel | 2 | 2009 | 1163 | 0.350 |
Why?
| | Bariatric Surgery | 2 | 2024 | 215 | 0.350 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 115 | 0.340 |
Why?
| | Animals | 23 | 2025 | 36823 | 0.340 |
Why?
| | Computed Tomography Angiography | 2 | 2022 | 125 | 0.340 |
Why?
| | Obesity, Morbid | 2 | 2024 | 259 | 0.340 |
Why?
| | Length of Stay | 4 | 2025 | 1205 | 0.340 |
Why?
| | Coitus | 1 | 2010 | 22 | 0.330 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2010 | 43 | 0.330 |
Why?
| | United States | 17 | 2025 | 14691 | 0.320 |
Why?
| | Ultrasonography, Doppler | 1 | 2010 | 123 | 0.320 |
Why?
| | Osteomyelitis | 1 | 2011 | 131 | 0.320 |
Why?
| | Body Mass Index | 3 | 2024 | 2375 | 0.310 |
Why?
| | Internet | 2 | 2011 | 647 | 0.310 |
Why?
| | Traumatology | 1 | 2009 | 26 | 0.310 |
Why?
| | Amputation, Traumatic | 1 | 2009 | 20 | 0.310 |
Why?
| | Follow-Up Studies | 9 | 2024 | 5106 | 0.310 |
Why?
| | Arteries | 2 | 2013 | 269 | 0.300 |
Why?
| | Hand Injuries | 1 | 2009 | 31 | 0.300 |
Why?
| | Suture Techniques | 2 | 2024 | 121 | 0.290 |
Why?
| | Magnetic Resonance Angiography | 1 | 2010 | 240 | 0.290 |
Why?
| | Vagina | 1 | 2010 | 186 | 0.280 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2008 | 20 | 0.280 |
Why?
| | Thigh | 1 | 2008 | 48 | 0.280 |
Why?
| | Wounds and Injuries | 2 | 2012 | 755 | 0.270 |
Why?
| | Reoperation | 5 | 2025 | 573 | 0.270 |
Why?
| | Hypertrophy | 2 | 2024 | 133 | 0.270 |
Why?
| | Skin Neoplasms | 3 | 2023 | 852 | 0.270 |
Why?
| | Sternum | 2 | 2024 | 24 | 0.270 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 93 | 0.270 |
Why?
| | Sternotomy | 2 | 2024 | 26 | 0.260 |
Why?
| | Orthopedics | 1 | 2009 | 142 | 0.260 |
Why?
| | Back | 1 | 2006 | 11 | 0.260 |
Why?
| | Cannabis | 2 | 2023 | 487 | 0.250 |
Why?
| | Internship and Residency | 3 | 2025 | 1132 | 0.250 |
Why?
| | Facial Paralysis | 1 | 2025 | 22 | 0.240 |
Why?
| | Histocompatibility | 3 | 2014 | 28 | 0.240 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2025 | 63 | 0.230 |
Why?
| | CD47 Antigen | 1 | 2025 | 38 | 0.230 |
Why?
| | Malpractice | 1 | 2025 | 45 | 0.230 |
Why?
| | Societies, Medical | 1 | 2009 | 816 | 0.230 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 26 | 0.230 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2025 | 30 | 0.230 |
Why?
| | Transplantation Conditioning | 3 | 2016 | 170 | 0.230 |
Why?
| | Implant Capsular Contracture | 1 | 2024 | 5 | 0.230 |
Why?
| | Cleft Lip | 1 | 2025 | 51 | 0.220 |
Why?
| | Physical Therapy Modalities | 2 | 2024 | 308 | 0.220 |
Why?
| | Anastomosis, Surgical | 3 | 2020 | 152 | 0.220 |
Why?
| | Gender Dysphoria | 1 | 2024 | 19 | 0.220 |
Why?
| | Fibula | 1 | 2024 | 43 | 0.220 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2025 | 99 | 0.220 |
Why?
| | Body Contouring | 1 | 2023 | 9 | 0.210 |
Why?
| | Malocclusion | 1 | 2023 | 24 | 0.210 |
Why?
| | Mandibular Fractures | 1 | 2023 | 11 | 0.210 |
Why?
| | Insurance | 1 | 2023 | 14 | 0.210 |
Why?
| | Sezary Syndrome | 1 | 2023 | 44 | 0.210 |
Why?
| | Publishing | 1 | 2025 | 145 | 0.210 |
Why?
| | Fetus | 2 | 2005 | 806 | 0.210 |
Why?
| | Skull Fractures | 1 | 2023 | 36 | 0.200 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 61 | 0.200 |
Why?
| | Hindlimb | 2 | 2003 | 128 | 0.200 |
Why?
| | Head and Neck Neoplasms | 2 | 2022 | 604 | 0.200 |
Why?
| | Seroma | 1 | 2022 | 3 | 0.190 |
Why?
| | Pain, Postoperative | 3 | 2023 | 265 | 0.190 |
Why?
| | Extremities | 2 | 2002 | 129 | 0.190 |
Why?
| | Weight Loss | 1 | 2008 | 776 | 0.190 |
Why?
| | Risk Factors | 7 | 2024 | 10326 | 0.190 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 2122 | 0.190 |
Why?
| | Clinical Protocols | 1 | 2023 | 267 | 0.190 |
Why?
| | Educational Measurement | 1 | 2024 | 281 | 0.180 |
Why?
| | Incidental Findings | 1 | 2022 | 87 | 0.180 |
Why?
| | Quality of Life | 4 | 2025 | 2878 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3555 | 0.180 |
Why?
| | Transplantation, Autologous | 3 | 2024 | 238 | 0.180 |
Why?
| | Hypotension | 1 | 2022 | 122 | 0.180 |
Why?
| | Proteus vulgaris | 1 | 2000 | 1 | 0.170 |
Why?
| | Mediastinitis | 1 | 2000 | 3 | 0.170 |
Why?
| | Proteus Infections | 1 | 2000 | 5 | 0.170 |
Why?
| | Cyclosporine | 3 | 2016 | 268 | 0.170 |
Why?
| | Medicaid | 1 | 2025 | 433 | 0.170 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 175 | 0.170 |
Why?
| | Motivation | 1 | 2025 | 567 | 0.170 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2014 | 385 | 0.170 |
Why?
| | Time Factors | 6 | 2014 | 6806 | 0.160 |
Why?
| | Flow Cytometry | 4 | 2020 | 1177 | 0.160 |
Why?
| | Blood Vessel Prosthesis | 1 | 2000 | 127 | 0.160 |
Why?
| | Keloid | 1 | 2019 | 7 | 0.150 |
Why?
| | Male | 18 | 2025 | 67309 | 0.150 |
Why?
| | Dermis | 1 | 2019 | 33 | 0.150 |
Why?
| | Antigens | 2 | 2016 | 357 | 0.150 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2000 | 131 | 0.150 |
Why?
| | Postoperative Period | 2 | 2023 | 342 | 0.150 |
Why?
| | Biomedical Research | 1 | 2025 | 688 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 992 | 0.150 |
Why?
| | Mice, SCID | 3 | 2025 | 366 | 0.150 |
Why?
| | Incidence | 2 | 2023 | 2792 | 0.140 |
Why?
| | Tattooing | 1 | 2018 | 14 | 0.140 |
Why?
| | Fluorouracil | 1 | 2019 | 208 | 0.140 |
Why?
| | Indocyanine Green | 2 | 2022 | 24 | 0.140 |
Why?
| | Chimera | 2 | 2011 | 58 | 0.140 |
Why?
| | Data Collection | 2 | 2011 | 668 | 0.130 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2017 | 83 | 0.130 |
Why?
| | Risk Assessment | 3 | 2024 | 3432 | 0.130 |
Why?
| | Graft vs Host Disease | 2 | 2016 | 248 | 0.130 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2016 | 74 | 0.130 |
Why?
| | Bupivacaine | 1 | 2016 | 32 | 0.130 |
Why?
| | Hernia, Ventral | 1 | 2016 | 24 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 2 | 2010 | 576 | 0.120 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 117 | 0.120 |
Why?
| | Surgical Mesh | 1 | 2016 | 47 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5742 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 60 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 509 | 0.120 |
Why?
| | Mental Disorders | 1 | 2024 | 1070 | 0.120 |
Why?
| | Prospective Studies | 3 | 2021 | 7572 | 0.120 |
Why?
| | Muscle, Skeletal | 2 | 2006 | 1710 | 0.120 |
Why?
| | Leukocytes | 1 | 2016 | 311 | 0.120 |
Why?
| | Databases, Factual | 3 | 2025 | 1351 | 0.120 |
Why?
| | Whole-Body Irradiation | 2 | 2012 | 78 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 868 | 0.110 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2014 | 50 | 0.110 |
Why?
| | Myeloablative Agonists | 1 | 2014 | 22 | 0.110 |
Why?
| | Cadaver | 2 | 2010 | 296 | 0.110 |
Why?
| | False Negative Reactions | 1 | 2014 | 53 | 0.110 |
Why?
| | Patient Selection | 2 | 2008 | 690 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1507 | 0.110 |
Why?
| | CD3 Complex | 1 | 2014 | 106 | 0.110 |
Why?
| | False Positive Reactions | 1 | 2014 | 115 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1798 | 0.110 |
Why?
| | Dissection | 1 | 2014 | 52 | 0.110 |
Why?
| | Temporal Arteries | 1 | 2014 | 45 | 0.110 |
Why?
| | Aged | 8 | 2025 | 23794 | 0.110 |
Why?
| | Allografts | 1 | 2014 | 146 | 0.110 |
Why?
| | Histocompatibility Antigens | 1 | 2014 | 105 | 0.110 |
Why?
| | Random Allocation | 1 | 2014 | 353 | 0.110 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 189 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 123 | 0.100 |
Why?
| | Health Care Costs | 1 | 2016 | 384 | 0.100 |
Why?
| | Pain Management | 1 | 2016 | 347 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3264 | 0.100 |
Why?
| | Multidetector Computed Tomography | 1 | 2013 | 39 | 0.100 |
Why?
| | Prostheses and Implants | 1 | 2014 | 143 | 0.100 |
Why?
| | Receptors, CCR4 | 2 | 2024 | 22 | 0.100 |
Why?
| | Recurrence | 2 | 2019 | 1055 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 267 | 0.090 |
Why?
| | Regional Blood Flow | 1 | 2014 | 473 | 0.090 |
Why?
| | Paternalism | 1 | 2011 | 4 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 851 | 0.090 |
Why?
| | Collagen | 1 | 2014 | 446 | 0.090 |
Why?
| | Beneficence | 1 | 2011 | 17 | 0.090 |
Why?
| | Marketing of Health Services | 1 | 2011 | 14 | 0.090 |
Why?
| | Hematopoiesis | 1 | 2012 | 190 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2025 | 600 | 0.090 |
Why?
| | Personal Autonomy | 1 | 2011 | 49 | 0.090 |
Why?
| | Intraoperative Care | 1 | 2011 | 49 | 0.090 |
Why?
| | Mice | 6 | 2025 | 17733 | 0.090 |
Why?
| | Antibodies, Monoclonal | 3 | 2024 | 1430 | 0.090 |
Why?
| | Ethics, Medical | 1 | 2011 | 84 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3405 | 0.090 |
Why?
| | Professional Practice | 1 | 2011 | 64 | 0.090 |
Why?
| | Treatment Failure | 1 | 2012 | 354 | 0.090 |
Why?
| | Neovascularization, Physiologic | 1 | 2011 | 178 | 0.080 |
Why?
| | Informed Consent | 1 | 2011 | 172 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2014 | 4281 | 0.080 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2010 | 39 | 0.080 |
Why?
| | Nutrition Assessment | 1 | 2010 | 91 | 0.080 |
Why?
| | Radiography, Abdominal | 1 | 2010 | 45 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1935 | 0.080 |
Why?
| | Logistic Models | 2 | 2016 | 2067 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1571 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2011 | 248 | 0.070 |
Why?
| | North America | 1 | 2009 | 312 | 0.070 |
Why?
| | Child | 5 | 2025 | 21822 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 664 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2009 | 562 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 738 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 328 | 0.070 |
Why?
| | Back Injuries | 1 | 2006 | 5 | 0.070 |
Why?
| | Wound Healing | 2 | 2023 | 328 | 0.070 |
Why?
| | Omentum | 1 | 2006 | 10 | 0.070 |
Why?
| | Infant | 3 | 2025 | 9398 | 0.070 |
Why?
| | Spinal Cord Injuries | 1 | 2010 | 212 | 0.060 |
Why?
| | Debridement | 1 | 2006 | 81 | 0.060 |
Why?
| | Case Management | 1 | 2006 | 66 | 0.060 |
Why?
| | Linear Models | 1 | 2008 | 846 | 0.060 |
Why?
| | Cytokines | 1 | 2014 | 2083 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1316 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 1058 | 0.060 |
Why?
| | Current Procedural Terminology | 1 | 2025 | 18 | 0.060 |
Why?
| | Operative Time | 1 | 2025 | 143 | 0.060 |
Why?
| | Major Histocompatibility Complex | 1 | 2005 | 227 | 0.060 |
Why?
| | Silicone Gels | 1 | 2024 | 4 | 0.060 |
Why?
| | Craniotomy | 1 | 2025 | 77 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2022 | 0.060 |
Why?
| | School Admission Criteria | 1 | 2024 | 27 | 0.060 |
Why?
| | Melanoma | 1 | 2012 | 757 | 0.060 |
Why?
| | Licensure, Medical | 1 | 2024 | 19 | 0.060 |
Why?
| | Burns | 1 | 2009 | 325 | 0.060 |
Why?
| | Proof of Concept Study | 1 | 2024 | 78 | 0.060 |
Why?
| | Esthetics | 1 | 2024 | 51 | 0.050 |
Why?
| | Pectoralis Muscles | 1 | 2024 | 18 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1089 | 0.050 |
Why?
| | Intraoperative Complications | 1 | 2025 | 138 | 0.050 |
Why?
| | Personnel Selection | 1 | 2024 | 78 | 0.050 |
Why?
| | Hydrocodone | 1 | 2023 | 17 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2025 | 6033 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 518 | 0.050 |
Why?
| | Adolescent | 4 | 2025 | 21382 | 0.050 |
Why?
| | Tobacco Use | 1 | 2023 | 64 | 0.050 |
Why?
| | Young Adult | 4 | 2024 | 13129 | 0.050 |
Why?
| | Chemoprevention | 1 | 2023 | 92 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 4143 | 0.050 |
Why?
| | Electromyography | 1 | 2025 | 401 | 0.050 |
Why?
| | Mandible | 1 | 2023 | 78 | 0.050 |
Why?
| | Tissue Donors | 1 | 2005 | 417 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5423 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2024 | 229 | 0.050 |
Why?
| | Physicians | 1 | 2011 | 907 | 0.050 |
Why?
| | Umbilicus | 1 | 2022 | 18 | 0.050 |
Why?
| | Genetic Testing | 1 | 2025 | 453 | 0.050 |
Why?
| | Transplantation Immunology | 1 | 2002 | 34 | 0.050 |
Why?
| | Peripheral Nerves | 1 | 2002 | 65 | 0.050 |
Why?
| | Perfusion | 1 | 2022 | 211 | 0.050 |
Why?
| | Pregnancy | 1 | 2014 | 6728 | 0.050 |
Why?
| | Cicatrix | 1 | 2022 | 64 | 0.040 |
Why?
| | Insurance, Health | 1 | 2023 | 280 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 558 | 0.040 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 72 | 0.040 |
Why?
| | Povidone-Iodine | 1 | 2000 | 11 | 0.040 |
Why?
| | Musculoskeletal System | 1 | 2001 | 48 | 0.040 |
Why?
| | Lymphocyte Depletion | 1 | 2001 | 135 | 0.040 |
Why?
| | Therapeutic Irrigation | 1 | 2000 | 77 | 0.040 |
Why?
| | Child, Preschool | 2 | 2025 | 11000 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 90 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 393 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 81 | 0.040 |
Why?
| | Students, Medical | 1 | 2024 | 339 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 481 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2000 | 126 | 0.040 |
Why?
| | Patient Readmission | 1 | 2025 | 694 | 0.040 |
Why?
| | Forelimb | 1 | 1999 | 29 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2022 | 613 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 303 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 2019 | 34 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2001 | 268 | 0.040 |
Why?
| | Lymphocytes | 1 | 2001 | 393 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2019 | 115 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 672 | 0.040 |
Why?
| | Medicare | 1 | 2024 | 758 | 0.040 |
Why?
| | Veterans | 1 | 2010 | 1466 | 0.040 |
Why?
| | Tacrolimus | 1 | 1999 | 199 | 0.040 |
Why?
| | Skin | 1 | 2003 | 751 | 0.040 |
Why?
| | Margins of Excision | 1 | 2017 | 50 | 0.030 |
Why?
| | Carcinoma, Lobular | 1 | 2017 | 49 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 805 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1350 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2019 | 337 | 0.030 |
Why?
| | Obesity | 2 | 2024 | 2982 | 0.030 |
Why?
| | Narcotics | 1 | 2016 | 52 | 0.030 |
Why?
| | Cost Savings | 1 | 2016 | 84 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2016 | 80 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 428 | 0.030 |
Why?
| | Nerve Block | 1 | 2016 | 73 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1124 | 0.030 |
Why?
| | Rats | 1 | 2024 | 5639 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 307 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 916 | 0.030 |
Why?
| | Tissue Expansion Devices | 1 | 2014 | 5 | 0.030 |
Why?
| | Tissue Expansion | 1 | 2014 | 10 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 678 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 667 | 0.030 |
Why?
| | Cellulitis | 1 | 2014 | 53 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2014 | 131 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5701 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 587 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 546 | 0.030 |
Why?
| | Leukocyte Transfusion | 1 | 2012 | 2 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1772 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2012 | 202 | 0.020 |
Why?
| | Fluorescence | 1 | 2011 | 160 | 0.020 |
Why?
| | Transcription Factors | 1 | 2019 | 1718 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2013 | 7585 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2024 | 2518 | 0.020 |
Why?
| | Burns, Electric | 1 | 2009 | 26 | 0.020 |
Why?
| | Equipment Design | 1 | 2011 | 521 | 0.020 |
Why?
| | Neurofibromatosis 1 | 1 | 2009 | 52 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1614 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 951 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4518 | 0.020 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 220 | 0.020 |
Why?
| | Smoking | 1 | 2014 | 1620 | 0.020 |
Why?
| | Recovery of Function | 1 | 2009 | 652 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 1032 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 239 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2001 | 153 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4190 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2004 | 1990 | 0.010 |
Why?
|
|
Mathes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|